$ORGO News
Last published 6d ago
- 6d agoORGOOrganogenesis Holdings Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoORGOOrganogenesis Holdings Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswireCANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations...
- 6d agoORGOOrganogenesis Holdings Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswireCANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 6d agoORGOOrganogenesis Holdings Inc. Third Quarter of Fiscal Year 2026 Earnings Conference Call - ORGANOGENESIS HOLDINGS INCEarnings Call TranscriptsWelcome, ladies and gentlemen, to the third quarter 2026 earnings conference call for Organogenesis Holdings, Inc. At this time, all participants have been placed in listen-only mode. Please note that this conference cal
- 1mo agoORGOOrganogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot UlcersGlobeNewswireCANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports
- 1mo agoORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026GlobeNewswireCANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 3mo agoORGOOrganogenesis Holdings Inc. Reports Second Quarter 2026 Financial ResultsGlobeNewswireCANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 3mo agoORGOOrganogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg UlcersGlobeNewswireCANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports
- 4mo agoCNXUABBVNVOEOLS+2One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsPR NewswireIn regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one...
- 4mo agoORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026GlobeNewswireCANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 4mo agoORGOOrganogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee OsteoarthritisGlobeNewswireCANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports
- 4mo agoCNXUIARTMDXGORGO+1Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild ItselfGlobeNewswireIssued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit
- 4mo agoCNXUIARTMDXGORGO+1The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding ItGlobeNewswireIssued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow
- 5mo agoCNXUIARTBVSORGO+1The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsPR NewswireFor more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't...
- 6mo agoORGOOrganogenesis Holdings Inc. First Quarter of Fiscal Year 2026 Earnings Conference Call - ORGANOGENESIS HOLDINGS INCEarnings Call TranscriptsWelcome, ladies and gentlemen, to the first quarter 2026 earnings conference call for Organogenesis Holdings, Inc. At this time, all participants have been placed in listen-only mode. Please note that this conference cal
- 6mo agoORGOOrganogenesis Holdings Inc. Reports First Quarter 2026 Financial ResultsGlobeNewswireCANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 6mo agoORGOOrganogenesis Completes Rolling Submission of Biologics License Application for ReNu®GlobeNewswireCANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions
- 7mo agoORGOOrganogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMGlobeNewswireStatistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting future coverage
- 7mo agoORGOOrganogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis PainGlobeNewswireClinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative
- 7mo agoORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026GlobeNewswireCANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 8mo agoORGOOrganogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record RevenueGlobeNewswireCANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 8mo agoORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026GlobeNewswireCANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for
- 10mo agoORGOAvista Healthcare Partners Announces PromotionsPR NewswireAvista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced three key promotions within...
- 10mo agoORGOOrganogenesis Announces Initiation of Biologics License Application for ReNu®GlobeNewswireCANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for
- 11mo agoORGOOrganogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis PainGlobeNewswireClinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative
- 1y agoORGOOrganogenesis Applauds CMS's Significant Step In Payment ReformGlobeNewswireCANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the "Company") (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
- 1y agoORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025GlobeNewswireCANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Provides Update on Second Phase 3 ReNu® StudyGlobeNewswireCompany maintains confidence in ReNu as innovative pain management therapy
- 1y agoORGOOrganogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireCANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoORGOOrganogenesis Holdings Inc. Reports Second Quarter 2025 Financial ResultsGlobeNewswireCANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025GlobeNewswireCANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued InnovationGlobeNewswireCANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. Reports First Quarter 2025 Financial ResultsGlobeNewswireCANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for
- 1y agoORGOOrganogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of EffectivenessGlobeNewswireCANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025GlobeNewswireCANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial ResultsGlobeNewswireCANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,
- 1y agoORGOOrganogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025GlobeNewswireCANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Expands Manufacturing Capacity to Support Future GrowthGlobeNewswireCANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Commends Final LCDsGlobeNewswireCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoORGOOrganogenesis Holdings Inc. Reports Third Quarter 2024 Financial ResultsGlobeNewswireCANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 1y agoORGOOrganogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred StockGlobeNewswireCANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 2y agoORGOOrganogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee OsteoarthritisGlobeNewswireCANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 2y agoORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024GlobeNewswireCANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 2y agoORGOOrganogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot UlcersGlobeNewswireRobust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements for Medicare coverage
- 2y agoORGOOrganogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireCANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
- 2y agoORGOOrganogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoORGOOrganogenesis Holdings Inc. Reports Second Quarter 2024 Financial ResultsGlobeNewswireCANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions